Improved cyclic urea inhibitors of the HIV-1 protease: Synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450

Chemistry and Biology

Volumn 3, Issue 4, 1996, Pages 301-314

  Hodge, C Nicholas ^a   Aldrich, Paul E ^a   Bacheler, Lee T ^a   Chang, Chong Hwan ^a   Eyermann, Charles J ^a   Garber, Sena ^a   Grubb, Mary ^a   Jackson, David A ^a   Jadhav, Prabharkar K ^a   Korant, Bruce ^a   Lam, Patrick Y S ^a   Maurin, Michael B ^a   Meek, James L ^a   Otto, Michael J ^a   Rayner, Marlene M ^a   Reid, Carol ^a   Sharpe, Thomas R ^a   Shum, Linyee ^a   Winslow, Dean L ^a   Erickson Viitanen, Susan ^a  

^a DUPONT COMPANY   (United States)

Author keywords

AIDS; Antiviral; Cyclic urea; HIV protease; Structure based drug design

Indexed keywords

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; UNIDENTIFIED RETROVIRUS;

AZEPINE DERIVATIVE; DRUG DERIVATIVE; MOZENAVIR; PROTEINASE INHIBITOR; UREA;

ANIMAL; ANTIBIOTIC RESISTANCE; ARTICLE; CHEMISTRY; DRUG EFFECT; ELECTRON MICROSCOPY; ENZYMOLOGY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; SOLUBILITY; SYNTHESIS; VIRUS REPLICATION; X RAY CRYSTALLOGRAPHY;

ADMINISTRATION, ORAL; ANIMALS; AZEPINES; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, MICROBIAL; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFUSIONS, INTRAVENOUS; MICE; MICROSCOPY, ELECTRON; SOLUBILITY; UREA; VIRUS REPLICATION;

EID: 0030113025     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(96)90110-6     Document Type: Article

References (59)

1. Appelt, K. (1993). Crystal structures of HIV-1 protease-inhibitor complexes. Perspect. Drug Discovery 1, 23-48.
2. Wlodawer, A. & Erickson, J.W. (1993). Structure-based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 62, 543-585.
3. Martin, J.A. (1992). Recent advances in the design of HIV proteinase inhibitors. Antiviral Res. 17, 265-278.
4. Gait, M.J. & Karn, J. (1995) Progress in anti-HIV structure-based drug design. TIBTECH 13, 430-437.
5. Kohl, N.E., et al., & Sigal, I.S. (1988). Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85, 4686-4690.
6. Peng, C., Ho, B.K., Chang, T.W. & Chang, N.T. (1989). Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J. Virol. 63, 2550-2556.
7. Kageyama, S., et al., & Mitsuya, H. (1994). A C2-symmetry-based HIV protease inhibitor, A77003, irreversibly inhibits infectivity of HIV-1 in vitro. AIDS Res. Hum. Retroviruses 10, 735-743.
8. Debouck, C. (1992). The HIV-1 protease as a therapeutic target for AIDS. AIDS Res. Hum. Retroviruses 8, 153-164.
9. Katz, R.A. & Skalka, A.M. (1994). The retroviral enzymes. Annu. Rev. Biochem. 63, 133-173.
10. Vacca, J. P., et al., & Huff, J.R. (1994). L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA 91, 4096-4100.
11. Kempf, D.J, et al., & Norbeck, D.W. (1995). ABT 538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92, 2484-2488.
12. Roberts, N.A., et al., & Martin, J.A. (1990). Rational design of peptide-based HIV protease inhibitors. Science 248, 358-361.
13. Reich, S.H., et al., & Shetty, B. (1995). Protein structure based design of potent orally bioavailable, nonpeptide inhibitors of human immunodeficiency virus protease. Proc. Natl. Acad. Sci. USA 92, 3298-3302.
14. Kim, E.E., et al., & Navia, M.A. (1995). Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J. Am. Chem. Soc. 117, 1181-1182.
15. Roberts, N.A. (1995). Drug-resistance patterns of Saquinavir and other HIV protease inhibitors. AIDS 9, S27-S32.
16. Markowitz, M., et al., & Ho, D.D. (1995). Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT 538, a novel protease inhibitor. J. Virol. 69, 701-706.
17. Condra, J.H., et al., & Emini, E.A. (1995). In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569-571.
18. Tisdale, M., et al., & (1995). Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob. Agents Chemother. 39, 1704-1710.
19. Lin, J.H., Chen, I.E., Vastag, KJ. & Ostovic, D. (1995). pH-Dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. Drug Metab. Dispos. 23, 730-735.
20. Muirhead, G.J., et al., & Houston, A.C. (1992). Pharmacokinetics of the HIV protease inhibitor Ro 318959, after single and multiple oral doses in healthy volunteers. Proc. British Pharmacological Soc. 34, 170P-171P.
21. Danner, S.A., et al., & Cooper, D.A. (1995). A short-term study of the safety, pharmacokinetics, and efficacy of Ritonavir, an inhibitor of HIV-1 protease. New. Eng. J. Med. 333, 1528-1533.
22. Livingston, D.J., et al., & Painter, G.R. (1995). Weak binding of Vx-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J. Infect. Diseases 172, 1238-1245.
23. Lam, P.Y.S., et al., & Erickson-Viitanen, S. (1994). Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science 263 380-384.
24. Wong, Y.N., et al., & Huang, S.-M. (1994). A pharmacokinetic evaluation of HIV protease inhibitors , cyclic ureas, in rats and dogs. Biopharm. Drug Dispos. 15, 535-544.
25. Erickson-Viitanen, S., Klabe, R.M., Cawood, P.G., O'Neal, P.L. & Meek, J.L (1994). Potency and selectivity of inhibition of human immunodeficiency virus protease by a small nonpeptide cyclic urea, DMP 323. Antimicrob. Agents Chemother. 38, 1628-1634.
26. Otto, M.J., et al., & Winslow, D.L. (1993). In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor. Antimicrob. Agents Chemother. 37, 2606-2611.
27. Rayner, M.M., et al., & Lam, P.Y.S. (1994). DMP 323, a nonpeptide cyclic urea inhibitor of human immunodeficiency virus (HIV) protease, specifically and persistently blocks intracellular processing of HIV gag polyprotein. Antimicrob. Agents Chemother. 38, 1635-1640.
28. Freudenberger, J.H., Konradi, A.W. & Pedersen, S.F. (1989). Intermolecular pinacol cross coupling of electronically similar aldehydes. An efficient and stereoselective synthesis of 1,2-diols employing a practical vanadium(II) reagent. J. Am. Chem. Soc. 111, 8014-8016.
29. Price, M.E. et al., & Emmett, G. (1996). Stereoselective synthesis of HIV protease inhibitor DMP 323. J. Org. Chem. 61,444-450.
30. Jadhav, P.K., McGee, LR., Shenvi, A. and Hodge, C. N. 1,4-diamino-2,3-dihydroxybutanes. 1991. World patent no. 9,214,696.
31. Lam, RY-S., Eyermann, C.J., Hodge, C.N., Jadhav, P.K. and DeLucca, G.V. Preparation of 2H-1,3-diazepinones as retroviral protease inhibitors. April 15, 1993. World patent no. 9,307,128.
32. Kempf, D.J., et al., & Norbeck, D.W. (1992). Stereocontrolled synthesis of C2-symmetric and pseudo-C2-symmetric diamino alcohols and diols for use in HIV protease inhibitors. J. Org. Chem. 57, 5692-5700.
33. King, R.W., et al., & Otto, M.J. (1995). Multiple mutations in the human immunodeficiency virus protease gene are responsible for decreased susceptibility to protease inhibitors. Antiviral Chem. Chemother. 6, 80-88.
34. Winslow, D.L., et al., & Otto M.J. (1995). Limited sequence diversity of the HIV type 1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors. AIDS Res. Hum. Retroviruses 11, 107-113.
35. Grzesiek, S., et al., & Torchia, D. (1994). NMR evidence for the displacement of a conserved interior water molecule in HIV protease by a non-peptide cyclic urea-based inhibitor. J. Am. Chem. Soc. 116, 1581-1582.
36. Yamazaki, T., et al., & Torchia, D. (1994). NMR and X-ray evidence that the HIV protease catalytic aspartyl groups are protonated in the complex formed by the protease and a non-peptide cyclic urea-based inhibitor. J. Am. Chem. Soc. 116, 10791-10792.
37. Thanki, N., et al., & Wlodawer, A. (1992). Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: comparisons with molecular modeling. Protein Sci. 1, 1061-1072.
38. Mulichak, A.M., et al., & Watenpaugh, K.D. (1993). The crystallographic structure of the protease from human immunodeficiency virus type 2 with two synthetic peptidic transition state analog inhibitors. J. Biol. Chem. 268, 13103-13109.
39. Hosar, M.V., et al., & Erickson, J.W. (1994). Influence of stereochemistry on activity and binding modes for C2 symmetry-based diol inhibitors of HIV-1 protease. J. Am. Chem. Soc. 116, 847-855.
40. Dreyer, G.B., et al., & Lewis, M. (1993). A symmetric inhibitor binds HIV-1 protease asymmetrically. Biochemistry 32, 937-947.
41. Ho, D.D., et al., & Markowitz, M. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126.
42. Wei, et al., & Shaw, G.M. (1995). Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122.
43. Coffin, J. (1995). HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 267, 483-489.
44. Kitchen, V.S., et al., & Weber, J.N. (1995). Safety and activity of Saquinavir in HIV infection. Lancet 345, 952-955.
45. Schatzl, H., Gelderblom, H., Nitschiko, H. & von der Helm, K. (1991). Analysis of non-infectious HIV particles produced in the presence of HIV proteinase inhibitor. Arch. Virol. 120, 71-81.
46. Gulnik, S., Bacheler, L., Tisdale, M. & Lamarre, D. (1995). In vitro resistance to protease inhibitors. Int. Antiviral News 3, S7-S9.
47. Bryant, M., et al., & Mueller, R. (1995). SC-52151, a novel inhibitor of the human immunodeficiency virus protease. Antimicrobial Agents Chemother. 39, 2239-2234.
48. Wolff, J.A., et al., & Chong, W. (1991). Conditions affecting direct gene transfer into rodent muscle in vivo. Biotechniques 11, 474-485.
49. Wolff, J.A., et al., & Feigner, P.L. (1990). Direct gene transfer into mouse muscle in vivo. Science 247, 1465-1468.
50. Rose, R.E., et al., & Lin, P.-F. (1996). Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc. Natl. Acad. Sci USA 93, 1648-1653.
51. Maurin, M.B., Vickery, R.D. & Hussain, M.A. (1995). Isolation and identification of a stable salt form of a novel HIV-1 protease inhibitor (DMP 450). Pharm. Res. 12, S-215.
52. Bacheler, LT., et al., & Miller, J.A. An assay for HIV RNA in infected cell lysates, and its use for the rapid evaluation of antiviral efficacy. Antiviral Chem. Chemother. 5, 111-121.
53. Japour, A.J., et al., & Crumpacker, C.S. (1993). Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37, 1095-1112.
54. Otto, M.J., et al., & Cheng, Y.-S. E. (1993). In vitro isolation and identification of HIV-1 variants with reduced sensitivity to C2 symmetrical inhibitors of HIV type 1 protease. Proc. Natl. Acad. Sci. USA 90, 7543-7547.
55. Winslow, D. L., et al., & Bacheler, L. T. (1994). Construction of infectious molecular clones of HIV-1 containing defined mutations in the protease gene. Biochem. Biophys. Res. Commun. 205, 1651-1657.
56. Sambrook, J., Fritsch, E. & Maniatis, T. (1989). Molecular Cloning Laboratory Manual. (2nd edn), Cold Spring Harbor Laboratory Press, New York.
57. Erickson, J., et al., & Knigge, M. (1990). Design, activity and 2.8 A crystal structure of a C2-symmetric inhibitor complexed to HIV-1 protease. Science 249, 527-533.
58. Brunger, A.T., Kuriyan, J. & Karplus, M. (1987). Crystallographic R factor refinement by molecular dynamics. Science 235, 458-460.
59. Gilson, M. & Honig, B. (1988). Calculation of the total electrostatic energy of a macromolecular system: solvation energies, binding energies and conformational analysis. Proteins 4, 7-18.